Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 13, 2024

Therapeutic Benefit of Larotrectinib vs Standard of Care in Locally Advanced or Metastatic Infantile Fibrosarcoma

ESMO Open

 

Additional Info

ESMO Open
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)
ESMO Open 2024 Apr 23;9(5)103006, D Orbach, M Carton, SK Khadir, M Feuilly, M Kurtinecz, C Vokuhl, E Koscielniak, G Pierron, L Lemelle, M Sparber-Sauer

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading